The DOI matches its Crossref record.
EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY
Open accessAbstract
SUMMARY: The glycaemic and lipid effects of treatment with pioglitazone in combination with a stable insulin regimen were evaluated in patients with type 2 diabetes. Patients (n=566) receiving stable insulin regimens for ≥30 days yet who had HbA 1c ≥8.0% and C‐peptide >0.7 μg/l were randomised to receive once‐daily 15 mg pioglitazone, 30 mg pioglitazone, or placebo in a 16‐week multicentre, double‐blind, placebo‐controlled trial. Per study protocol, the insulin dose was to remain unchanged, but could be decreased in response to hypoglycaemia. At the end of double‐blind treatment, patients receiving pioglitazone (15 mg or 30 mg) showed statistically significant mean decreases relative to baseline HbA 1c (‐1.0 and ‐1.3, respectively; p<0.0001) and fasting plasma glucose (FPG) (‐34.5 mg/dl [‐1.92 mmol/l] and ‐48.0 mg/dl [‐2.67 mmol/l], respectively; p<0.0001); these differences compared with placebo were also significant (p<0.0001). Pioglitazone (15 or 30 mg) yielded significant increases in HDL‐C levels (mean increases ranging from +7.1% to + 9.3%) compared with baseline or placebo (p<0.01). The 30 mg dose also significantly reduced mean triglyceride levels (‐23.7%) compared with placebo (p=0.0218). No consistent changes in TC or LDL‐C levels were observed. The incidence of adverse events was similar in all treatment groups, although the incidences of weight increase, hypoglycaemia and oedema were higher among patients receiving insulin plus pioglitazone. There was no evidence of hepatotoxicity or drug‐induced elevations of serum ALT ≥3 x ULN. Pioglitazone, when added to stable insulin regimens, significantly improved HbA 1c and FPG in type 2 diabetes. Pioglitazone treatment also provided significant benefit with respect to plasma HDL‐C and triglyceride levels. Whether these lipid changes have an impact on overall diabetic complications remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY. https://app.cochat.ai/papers/10.1111/j.1742-1241.2002.tb11251.x
- The paper
- Rosenstock, J., Einhorn, D., Hershon, K., Glazer, N., & Yu, S. (2002). EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2002.tb11251.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.